Cite
HARVARD Citation
Van Cutsem, E. et al. (n.d.). 2139 CONSIGN: An open-label phase 3B study of regorafenib in patients with metastatic colorectal cancer (mCRC) who failed standard therapy. European journal of cancer. pp. S378-S379. [Online].